loading page

ZFX expression is connected with improved survival in patients with breast cancer
  • +5
  • Kristian Mcarthur,
  • Gideon Carney,
  • Duncan Bush,
  • Scarlet Sellers,
  • Roan Carpenter,
  • James K,
  • Maira Hewitt,
  • Alistair Molloy
Kristian Mcarthur
Bio-Tech Research and Development Institute, UWI
Author Profile
Gideon Carney
Bio-Tech Research and Development Institute, UWI
Duncan Bush
Bio-Tech Research and Development Institute, UWI
Scarlet Sellers
Bio-Tech Research and Development Institute, UWI
Roan Carpenter
Bio-Tech Research and Development Institute, UWI
James K
Bio-Tech Research and Development Institute, UWI
Maira Hewitt
Bio-Tech Research and Development Institute, UWI
Alistair Molloy
Bio-Tech Research and Development Institute, UWI

Abstract

We analyzed published tumor transcriptome data in conjunction with linked survival data to identify genes linked with breast cancer survival outcomes (1, 2). When comparing tumor transcriptomes based on 24-month survival, we discovered that the zinc-finger protein X-linked ZFX (3, 4) was among the most differentially expressed genes in both original and metastatic tumor tissues. ZFX expression was considerably enhanced in metastatic tumors of patients who survived more than 24 months, indicating that enhanced ZFX expression offers a survival advantage for patients with stage IV metastatic breast cancer.